--- title: "Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq" url: "https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-10-06" section: "Listings" tickers: "NASDAQ:DCOY" source: "https://www.sec.gov/Archives/edgar/data/1615219/000161521925000142/flks-20251006.htm" summary: "Salarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 m" --- By the aibio.space news desk. Sources - [Decoy Therapeutics Inc. 8-K (2025-10-06)](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000142/flks-20251006.htm) - [Decoy Therapeutics Inc. 10-K (2025-03-21): business](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000037/flks-20241231.htm) [DCOY](https://aibio.space/companies/decoy-therapeutics/) 2025-10-06 # Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum Tickers [DCOY](https://aibio.space/companies/decoy-therapeutics/) Salarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance. ## Key facts - **Company**: Decoy Therapeutics Inc. (NASDAQ: DCOY) - **News type**: Listings - **Primary source**: [Decoy Therapeutics Inc. 8-K (2025-10-06)](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000142/flks-20251006.htm) *Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.* Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) said in a Form 8-K dated October 6, 2025 that it believes its stockholders' equity again exceeds the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). The company had until October 20, 2025 to regain compliance with that rule. The filing is signed by Mark J. Rosenblum as acting chief executive officer and executive vice president and chief financial officer. Since June 30, 2025, the company issued and sold 434,882 shares of common stock for gross proceeds of $2.4 million under an at-the-market offering agreement with Ladenburg Thalmann & Co. Inc., dated February 5, 2021. It also sold 367,887 shares for gross proceeds of $3.8 million to C/M Capital Master Fund, LP under a securities purchase agreement dated December 12, 2024. Those two sales are the basis for the company's view that equity now exceeds the minimum. ## What the company expects to report The company expects its quarterly report for the period ended September 30, 2025 to show stockholders' equity above $2.5 million as of that date. It says it is awaiting Nasdaq's confirmation that it has evidenced compliance. The company's determination is based on estimates available as of the date of the 8-K. It is not a comprehensive statement of results or position for the quarter, and it has not been audited by the company's independent accounting firm. The filing also says the company's financial closing procedures for the quarter are not complete, so stockholders' equity when those procedures finish may differ from the preliminary estimate. The 8-K does not give the equity figure itself. It gives only the conclusion that equity exceeds $2.5 million. The filing lists a risk factor that the company has a history of noncompliance with Nasdaq listing standards and cannot guarantee that there will be no future noncompliance. It adds that a delisting would bring a correlative loss of market value and liquidity for the common stock. ## The sales behind the compliance The C/M Capital sales were made under a securities purchase agreement dated December 12, 2024. The October 6 8-K does not describe that agreement beyond its date and parties, and it does not give the price per share in either sale. The at-the-market sales with Ladenburg were made into the open market. The 8-K gives no commission rate for them and no average price. The company does not say whether it expects to keep using either source at the same pace. ## The business and the merger it is pursuing The company's annual report, filed March 21, 2025, describes Salarius as a clinical-stage biopharmaceutical company developing treatments for cancers caused by dysregulated gene expression. Its pipeline then included SP-3164, a targeted protein degrader, and seclidemstat, a targeted protein inhibitor. The report says a lack of funding required the company to curtail spending needed to begin the clinical trial for SP-3164, and that it closed a Phase 1/2 trial of seclidemstat in Ewing sarcoma in July 2024 to conserve cash. The same annual report describes the merger with Decoy Therapeutics, under which Decoy would continue as a wholly owned subsidiary of Salarius. The exchange ratio assumed a base value of $28.0 million for Decoy and $4.6 million for Salarius, before adjustments for cash at closing. The company agreed to call a special stockholder meeting to approve the conversion of the preferred stock, a new equity incentive plan and, if necessary, a reverse stock split. ## What the filing leaves out The 8-K does not give Salarius's cash balance, net loss or share count after the sales. It does not state a share price for either sale or the stock's trading price in October. The status of the reverse split proposal is not addressed in the filing. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story DCOY Decoy Therapeutics Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq", 2025-10-06, https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/